Unique ID issued by UMIN | UMIN000009810 |
---|---|
Receipt number | R000011499 |
Scientific Title | Clinical evaluation of time to re-hospitalization and renal function of tolvaptan in congestive heart failure patients with volume overload. Prospective randomized controlled trial. |
Date of disclosure of the study information | 2013/01/19 |
Last modified on | 2013/01/19 14:13:14 |
Clinical evaluation of time to re-hospitalization and renal function of tolvaptan in congestive heart failure patients with volume overload. Prospective randomized controlled trial.
Clinical evaluation of time to re-hospitalization and renal function of tolvaptan in congestive heart failure patients with volume overload. Prospective randomized controlled trial.
Clinical evaluation of time to re-hospitalization and renal function of tolvaptan in congestive heart failure patients with volume overload. Prospective randomized controlled trial.
Clinical evaluation of time to re-hospitalization and renal function of tolvaptan in congestive heart failure patients with volume overload. Prospective randomized controlled trial.
Japan |
congestive heart failure
Cardiology |
Others
NO
To evaluate the effectiveness of tolvaptan for improvements in renal function and time to re-hopitalization in congestive heart failure patients with volume overload.
Efficacy
The rate of change of serum creatinine
body weight, daily urine volume, dyspnea, congestive findings(leg edema, jugular vein dilatation, pulmonary congestion ), serum sodium, serum potassium, cystitis C, time to re-hospitalization.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
3
Treatment
Medicine |
Conventional therapy only
Conventional therapy with 14 days administration of tolvaptan 7.5mg/day.
Conventional therapy with 7 days administration of tolvaptan 15mg/day.
20 | years-old | <= |
90 | years-old | >= |
Male and Female
Congestive heart failure patients to administrating loop diuretics with volume overload in hospital.
1) Patients who a history of hypersensitivity to tolvaptan
2) Patients with severe hypotention or cardioganic shock
3) Patients with cardiac assist device
4) Patients with dehydration
5) Patients with systolic blood pressure < 90mmHg
6) Patients with serum Na > 147 mEq/L or serum K > 5.5 mEq/L or T- bilirubin > 3.0 mg/dL
7)Patients considered not eligible for the study by the attending doctor due to other reasons
180
1st name | |
Middle name | |
Last name | Shunsuke Take |
Saiseikai Noe hospital
Department of cardiology
1-3-25, furuichi, joto-ku, osaka city
1st name | |
Middle name | |
Last name | Yoshihiro kato |
Saiseikai Noe hospital
Department of cardiology
1-3-25, furuichi, joto-ku, osaka city
0669320401
Saiseikai Noe hospital
Department of cardiology
Saiseikai Noe hospital
Self funding
NO
2013 | Year | 01 | Month | 19 | Day |
Unpublished
Enrolling by invitation
2012 | Year | 11 | Month | 01 | Day |
2012 | Year | 11 | Month | 01 | Day |
2016 | Year | 03 | Month | 31 | Day |
2016 | Year | 03 | Month | 31 | Day |
2013 | Year | 01 | Month | 19 | Day |
2013 | Year | 01 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011499